Julie Rehmeyer's 'Through the Shadowlands'
Writer Never Give Up talks about Julie Rehmeyer's new book "Through the Shadowlands: A Science Writer's Odyssey into an Illness Science Doesn't Understand" and shares an interview with Julie ...
Discuss the article on the Forums.

Response to Rituximab may be sustained or transient -

Discussion in 'Other Health News and Research' started by Marco, Jan 23, 2016.

  1. Marco

    Marco Grrrrrrr!

    Messages:
    2,379
    Likes:
    3,180
    Near Cognac, France
    - Depending on the autoimmune disease and where the normal immune 'checkpoints' break down.

    This is an interesting paper on the dynamics of the response to Ritux treatment of Type I diabetes (interesting in itself - I wasn't aware it was being trialled).

    It appears that the therapeutic response in T1D is transient and likely to be so in other autoimmune diseases characterised by early 'central' (in the thymus and bone marrow) B cell tolerance impairment (e.g. T1D; RA; SLE). In contrast those with a specific defective peripheral B cell tolerance checkpoint (e.g. Multiple Sclerosis) may have a more sustained remission.

    Rituximab does not reset defective early B cell tolerance checkpoints


    http://www.jci.org/articles/view/83840
     
    Battery Muncher, zzz, ahmo and 4 others like this.

See more popular forum discussions.

Share This Page